BRAF and melanoma: For instance, targeted therapies (such as BRAF inhibitors and MEK inhibitors) have been shown to potentiate immune checkpoint inhibitor activity in preclinical models (168), but when used together in melanoma patients severe irAEs were observed forcing closure of the study (169, 170).